License and Royalty Revenue (Tables)

12 Months Ended

Dec. 31, 2022

Schedule Of License and Royalty Revenue

License and royalty revenue consisted of the following (in thousands):

	Years Ended December 31,
	2022		2021		2020
Zolgensma royalties	$	101,919	$	94,978	$	61,631
Achievement of sales-based milestone for Zolgensma		—		—		80,000
AbbVie collaboration and license agreement		—		370,000		—
Other license and royalty revenue		10,805		5,369		12,936
Total license and royalty revenue	$	112,724	$	470,347	$	154,567

Novartis Gene Therapies [Member]

Schedule Of License and Royalty Revenue

The Company recognized the following amounts under the Novartis License (in thousands):

	Years Ended December 31,
	2022		2021		2020
Zolgensma royalties	$	101,919	$	94,978	$	61,631
Achievement of sales-based milestone for Zolgensma		—		—		80,000
Other license revenue		31		—		3,500
Total license and royalty revenue	$	101,950	$	94,978	$	145,131
Interest income from licensing	$	92	$	22	$	26